# Anthony Aiudi

> Anthony Aiudi is a Series A investor at Morningside backing Biotechnology and Medical. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Morningside](https://shizune.co/investors/profile/morningside-technology-ventures)
- Total investments: 6
- Last investment: Jul 2026
- Lead investor: 67%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/anthonyaiudi/

Anthony Aiudi is a Series A investor at Morningside focused on Biotechnology and Medical. Anthony Aiudi - Investment Professional @ Morningside

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 50% |
| Medical | 2 | 33% |
| Therapeutics | 2 | 33% |
| Pharmaceutical | 2 | 33% |
| Beauty | 1 | 17% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 33% |
| Series B | 2 | 33% |
| Series C | 1 | 17% |
| Series D | 1 | 17% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 50% |
| Australia | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| AdvanCell | AdvanCell is an Australian radiopharmaceutical firm in the clinical stages that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatment. | $315M | Series D | Jul 15, 2026 |  |
| AdvanCell | AdvanCell is an Australian radiopharmaceutical firm in the clinical stages that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatment. | $112M | Series C | Feb 03, 2025 |  |
| Valitor | Valitor, Inc. has developed novel methods of modifying therapeutic proteins to achieve substantial control over their pharmacokinetics, target specificity and bioactivity. Their technology platform can be broadly applied to improve the pharmacological properties of many protein drugs that are currently approved or under development. They currentlyhave three development pipelines in the fields of dermatology, ophthalmology, and orthopedics that highlight the capabilities of their novel drug products.​ | $28M | Series B | Oct 05, 2022 |  |
| Otolith Labs | Otolith Labs has developed a novel wearable medical device that is on track to be the first FDA approved device for the treatment of vertigo through the De Novo process in 2023. The technology provides immediate relief of symptoms in approximately 80% of vertigo cases based on pilot clinical data. Otolith Labs has received $1.8 million in contractsfrom the US Department of Defense to further develop the technology for their personnel needs. | $20M | Series A | Sep 07, 2022 |  |
| AdvanCell | AdvanCell is an Australian radiopharmaceutical firm in the clinical stages that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatment. | $12.5M | Series B | Aug 23, 2022 |  |
| Fount Bio | Fount Bio is a life science company that applies proprietary advances in glycopolymer research for skin health. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts, United States. | $8.2M | Series A | Jul 01, 2021 |  |

6 of 6 investments shown.

## Co-investors
- [Sanofi Ventures](https://shizune.co/investors/profile/sanofi-genzyme-bioventures) — VC Fund, 2 deals together
- [SV Health Investors](https://shizune.co/investors/profile/sv-life-sciences) — VC Fund, 2 deals together
- [SymBiosis](https://shizune.co/investors/profile/symbiosis-ce11) — VC Fund, 2 deals together
- [Tenmile](https://shizune.co/investors/profile/tenmile) — VC Fund, 2 deals together
- [Abingworth](https://shizune.co/investors/profile/abingworth-management) — VC Fund, 1 deal together
- [Berkeley Catalyst Fund (BCF)](https://shizune.co/investors/profile/berkeley-catalyst-fund-bcf) — VC Fund, 1 deal together

## About Morningside

VC Fund · Shanghai, China

Morningside makes venture capital investments in companies with novel science and technology. We are characterized by a long-term outlook in company-building and an unwavering commitment to acting ethically.Based in the greater Boston area, our team of entrepreneurial investment professionals has deep experience in life sciences, digital health,AI, materials and technology.Founded in 1986 as a family office for the Chan family, charitable commitments to education, research and healthcare include the Harvard T.H. Chan School of Public Health, the UMass Chan Medical School, and the MIT Morningside Academy for Design.

5 contacts available at Morningside.

| Name | Title | Profile |
| --- | --- | --- |
| Anthony Aiudi | Investment Professional | https://shizune.co/investors/profile/anthony-aiudi |
| Mick Sawka | Investment Manager | https://shizune.co/investors/profile/mick-sawka |
| Gerald Chan | Co-Founder, Investment Director & Board Member | https://shizune.co/investors/profile/qin-liu-f6a9 |
| Justin Burns | Investment Professional | https://shizune.co/investors/profile/justin-burns-de33 |
| Michael Xue | Managing Director | https://shizune.co/investors/profile/michael-xue-bf20 |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Anthony Aiudi invest in?

Anthony Aiudi invests primarily in Biotechnology, Medical and Therapeutics startups, most often at Series A and Series B stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Anthony Aiudi last invest?

The most recent investment recorded for Anthony Aiudi closed in Jul 2026. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co